Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

ALZN
Alzamend Neuro, Inc. Common Stock
stock NASDAQ

At Close
May 8, 2025 3:58:30 PM EDT
0.5400USD-9.396%(-0.0560)478,819
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 8, 2025 9:18:30 AM EDT
0.5650USD-5.201%(-0.0310)137,668
After-hours
May 8, 2025 4:50:30 PM EDT
0.5800USD+7.407%(+0.0400)66,017
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 13, 2022
11:49AM EST  ALZN: Coordinated Offensive on Alzheimer's Disease   Benzinga
Dec 17, 2021
09:23AM EST  Alzamend Neuro CEO To Appear On Todd Ault Podcast Mon. Dec. 20   Benzinga
09:13AM EST  BitNile Holdings Founder Tweets 'Just amazing data! My opinion. Wow $ALZN'   Benzinga
09:01AM EST  Alzamend Neuro Announces Topline Data From Phase 1 First-in-Human Clinical Trial For AL001 Treatment Of Dementia Related To Alzheimer's; Data showed AL001 Is 'bioequivalent to the marketed lithium carbonate product'   Benzinga
Dec 14, 2021
02:19PM EST  Ault Global Founder Tweets 'Should the Company exercise all warrants and options to invest, it would own approximately 22.6 million shares with an average cost of $2.27 per share of common stock...'   Benzinga
12:40PM EST  'Yes $NILE through its Subsidiary Ault Alliance owns a large position in $ALZN please see SEC filings. We have plans to spin off Ault Alliance as disclosed by the prior press release' -Tweet From Ault Global Chair   Benzinga
Nov 30, 2021
04:48PM EST  Alzamend Neuro Announces Topline Data For Phase 1 Trial Of AL001 For Dementia Related to Alzheimer's Will Be Delivered Mid-To-Late Dec. 2021; IND Submission For Combined AL002 Phase 1/2 Clinical Trial Expected In Second Quarter Of 2022   Benzinga
Nov 24, 2021
05:20AM EST  Alzamend Neuro 10%+ Owner Milton C Ault III Reported Purchase of 19,681 Shares @ Avg Price of $1.92/Share in Form 4 Filing on Tuesday   Benzinga
Nov 10, 2021
06:43PM EST  Alzamend Neuro Reports In Form4 Filing Ault Milton Buys 145K Shares   Benzinga
Oct 1, 2021
10:03AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 1, 2021   Benzinga
07:56AM EDT  The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO   Benzinga
07:13AM EDT  Ascendiant Capital Initiates Coverage On Alzamend Neuro with Buy Rating, Announces Price Target of $8   Benzinga
Sep 30, 2021
11:54AM EDT  Why Alzamend Neuro Shares Are Surging Higher Today   Benzinga
10:12AM EDT  Alzamend Neuro Receives Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease   Benzinga
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
Sep 23, 2021
07:57AM EDT  The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
Sep 16, 2021
10:21AM EDT  ALZN: An Elemental Approach to Alzheimer's Disease   Benzinga
Sep 15, 2021
07:38AM EDT  The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs   Benzinga
Sep 14, 2021
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
Sep 13, 2021
06:31AM EDT  Alzamend Neuro Announces Initiation Of Phase I First-In-Human Clinical Trial For AL001 For Dementia Related To Alzheimer's Disease   Benzinga
Aug 27, 2021
07:35AM EDT  The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration   Benzinga
Aug 26, 2021
08:09AM EDT  The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO   Benzinga
Aug 18, 2021
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
08:01AM EDT  Alzamend Neuro Announces It Has Contracted With Altasciences To Conduct A Phase I Relative Bioavailability Study for AL001 For Dementia Related To Alzheimer's Disease In September 2021   Benzinga
Aug 13, 2021
07:43AM EDT  The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO   Benzinga
Aug 10, 2021
02:42PM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Aug 6, 2021
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
06:42AM EDT  Ault Global Holdings Announces Additional Investment in Alzamend Under Alzamend's Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Alzamend   Benzinga
05:27AM EDT  Milton Ault III Reported Purchase of 2,007,560 Shares of Alzamend Neuro, Inc @ Avg Price of $1.02/Share in Form 4 Filing on Tuesday   Benzinga
Jul 30, 2021
06:32AM EDT  Alzamend Neuro Reports Pre-Investigational New Drug Application Submission For Its Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's   Benzinga
Jul 28, 2021
03:07PM EDT  Alzamend Neuro Receives FDA "Study May Proceed" Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease   Benzinga
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
06:34AM EDT  Alzamend Neuro Highlights Receipt Of Toxicology Results For AL002 Ij GLP Toxicology Study Using A Transgenic Mouse Model Of Alzheimer's Disease   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 19, 2021
10:21AM EDT  Mid-Morning Market Update: Markets Open Lower; AutoNation Profit Beats Estimates   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jul 1, 2021
10:51AM EDT  Alzamend Neuro shares were trading higher after the company announced it submitted an Investigational New Drug application to the US FDA for the initiation of a Phase 1 clinical study of AL001.   Benzinga
08:07AM EDT  The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts   Benzinga
06:48AM EDT  Ault Global Holdings Announces That Alzamend Neuro Has Submitted an IND Application for AL001 for Dementia Related to Alzheimer's Disease   Benzinga
06:35AM EDT  Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease   Benzinga
Jun 23, 2021
07:35AM EDT  The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway   Benzinga
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 18, 2021
07:46AM EDT  The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs   Benzinga
Jun 17, 2021
08:33AM EDT  The Daily Biotech Pulse: Biogen Faces Another Clinical Setback, CureVac's COVID-19 Vaccine Study Fails, Moment Of Reckoning For Orphazyme   Benzinga
Jun 16, 2021
10:17AM EDT  Mid-Morning Market Update: Markets Mixed; Elanco Animal Health To Acquire Kindred Biosciences   Benzinga
05:02AM EDT  44 Biggest Movers From Yesterday   Benzinga
Jun 15, 2021
10:50AM EDT  CORRECTION: Ault Global Holdings Shares Spike Higher; Traders Circulate Stake Co Has In Recent IPO Alzamend Neuro; Co Owns 3.4M Shares Of Alzamend Neuro   Benzinga
10:50AM EDT  Ault Global Holdings Shares Spike Higher; Traders Circulate Stake Co Has In Recent IPO Alzamend Neuro; Co Owns 3.4M Shares Of Alzamend Neuro   Benzinga
10:47AM EDT  Alzamend Neuro Shares Open For Trade At $29; IPO Priced $5/Share   Benzinga
09:23AM EDT  Alzamend Neuro Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced $5/Share   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC